VK-2019
Phase 2Small molecule
VK-2019 is one of 5 small molecule programs targeting Nasopharyngeal Cancer. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Nasopharyngeal Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Opdivo
Bristol-Myers SquibbPhase 2
Mitoxantrone Hydrochloride Liposome
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 2
VK-2019
CCullinan Therapeutics Inc.
Phase 2
Cisplatin and Gemcitabine
NNational University Hospital, Singapore
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Nasopharyngeal Carcinoma1 trial
Diffuse Large B Cell Lymphoma Refractory1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VK-2019. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCullinan Therapeutics Inc.